Testosterone Therapy in Adult-Onset Testosterone Deficiency: Hematocrit and Hemoglobin Changes-Reference-Cited by-同舟云学术

Testosterone Therapy in Adult-Onset Testosterone Deficiency: Hematocrit and Hemoglobin Changes

Published:2021-09-01 Issue:1 Volume:2 Page:141-149
ISSN:2689-4653
Container-title:Androgens: Clinical Research and Therapeutics
language:en
Short-container-title:Androgens: Clinical Research and Therapeutics

Author:

Lorde Nathan¹,Maarouf Amro¹,Strange Richard C.²,König Carola S.³,Hackett Geoff⁴^ORCID,Haider Ahmad⁵,Haider Karim Sultan⁵^ORCID,Desnerck Pieter⁶,Saad Farid⁷⁸^ORCID,Ramachandran Sudarshan¹²³⁹^ORCID

Affiliation:

1. Department of Clinical Biochemistry, University Hospitals Birmingham NHS Foundation Trust, West Midlands, England, United Kingdom.

2. Institute for Science and Technology in Medicine, Keele University, Staffordshire, United Kingdom.

3. Department of Mechanical and Aerospace Engineering, Brunel University London, United Kingdom.

4. School of Health and Life Sciences, Aston University, Birmingham, United Kingdom.

5. Praxis Dr. Haider, Bremerhaven, Germany.

6. Department of Engineering, University of Cambridge, Cambridge, United Kingdom.

7. Medical Affairs Andrology, Bayer AG, Berlin, Germany.

8. Gulf Medical University School of Medicine, Ajman, UAE.

9. Department of Clinical Biochemistry, University Hospitals of North Midlands, Staffordshire, United Kingdom.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/andro.2021.0013

Reference51 articles.

1. Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes

2. British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice

3. Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis

4. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes

5. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins